NewEdge Wealth LLC Sells 26,519 Shares of Pfizer Inc. $PFE

NewEdge Wealth LLC lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 24.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 81,237 shares of the biopharmaceutical company’s stock after selling 26,519 shares during the quarter. NewEdge Wealth LLC’s holdings in Pfizer were worth $2,281,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Norges Bank purchased a new position in Pfizer in the 4th quarter worth about $1,830,986,000. Morgan Stanley boosted its position in Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after buying an additional 14,342,946 shares during the period. Bank of New York Mellon Corp boosted its position in Pfizer by 38.9% in the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock valued at $1,208,023,000 after buying an additional 13,581,757 shares during the period. Janus Henderson Group PLC grew its stake in Pfizer by 577.5% in the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock worth $218,817,000 after acquiring an additional 7,489,189 shares in the last quarter. Finally, Capital World Investors increased its position in shares of Pfizer by 51.5% during the fourth quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company’s stock worth $533,704,000 after acquiring an additional 7,287,194 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.9%

PFE stock opened at $24.52 on Friday. The stock has a market capitalization of $139.78 billion, a PE ratio of 18.72 and a beta of 0.35. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a 50 day moving average of $25.11 and a 200 day moving average of $26.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period last year, the business earned $0.92 earnings per share. Pfizer’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced that PF-08057418 cleared a Phase 1 safety milestone, which helps reinforce confidence in the company’s research pipeline and early-stage development prospects. Article: Pfizer’s PF-08057418 Clears Phase 1 Safety Milestone, Offering a Quiet Boost to Pipeline Confidence
• Positive Sentiment: Pfizer is advancing PF-08653945 into an early-stage obesity trial, giving investors another potential growth driver in a large and competitive therapeutic market. Article: Pfizer Advances New Obesity Shot With Early Stage Trial of PF-08653945
• Positive Sentiment: The FDA granted Priority Review to Pfizer’s Talzenna plus Xtandi regimen for metastatic prostate cancer, which improves the odds of a faster regulatory decision and supports oncology revenue upside if approved. Article: FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
• Neutral Sentiment: Unusual call option activity suggests traders are positioning for a move in Pfizer shares, but it does not by itself confirm a fundamental change in the company’s outlook.
• Neutral Sentiment: Recent commentary on Pfizer’s dividend yield and oncology valuation highlights that investors are still weighing income appeal against execution and growth concerns.
• Negative Sentiment: Expanded patent litigation tied to Pfizer’s mRNA vaccine business remains a potential overhang, adding legal and operational uncertainty that could pressure sentiment if the dispute escalates. Article: Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Citigroup boosted their price target on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. lowered their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Guggenheim dropped their price target on Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday, July 13th. Finally, Wolfe Research reissued an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.50.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.